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The endocrine system is composed of glands that secrete 
chemical messengers (hormones) that interact with spe-
cific targets (receptors). These interactions lead to the 
regulation of a vast set of functions, including growth, 
development, reproduction, energy balance, metabolism 
and body weight regulation1. Exogenous chemicals can 
inadvertently interfere with this complex communica-
tion system and cause adverse health effects. Throughout 
their lives, humans and other animals are exposed to 
a wide array of these so- called endocrine- disrupting 
chemicals (EDCs) through their encounters with work, 
consumer products, medications, natural resources, 
military service and other circumstances. This expo-
sure can increase the risk of reproductive impairment2–4, 
cognitive deficits5–7, metabolic diseases and disorders8,9 
and various cancers10–13, among others. The mechanisms 
by which hormones and EDCs exert specific actions are 
dependent on specific actions at the cellular and tissue 
levels as well as on circadian rhythms, seasonal changes, 
life stage and sex14. Moreover, the developmental, circa-
dian or pulsatile pattern of hormone secretion can be an 
important component of their signalling mechanism and 
EDCs can interfere with this pattern15–17. Indeed, the risk 
of lifelong adverse health effects is enhanced when peri-
ods of EDC exposure coincide with the formation and 
differentiation of organ systems in early development18.
Although defining a chemical as an EDC is not a 
primary concern in all jurisdictions, an important key 
first step in governing exposures to chemicals with 
EDC properties is the identification of their intrinsic 
hazard. Regulatory agencies use various approaches 
to evaluate the available evidence, including for EDC 
identification19–24, but they can differ in the end points 
analysed and in their methods for gathering and inter-
preting the scientific evidence. Thus, standard, system-
atic approaches to organize and evaluate the often 
complex mechanistic data on a given chemical would 
reduce the likelihood of different jurisdictions arriving 
at different conclusions for hazard evaluations25,26.
Similar challenges were previously encountered in 
the evaluation of mechanistic data for cancer hazard 
identification. Therefore, the key characteristics (KCs) 
of human carcinogens were developed, providing a uni-
form basis for searching, organizing and evaluating 
mechanistic evidence to support the identification of 
carcinogens27. This KC- based approach is becoming 
widely applied by authoritative bodies, including the 
International Agency for Research on Cancer (IARC) 
and the National Toxicology Program, as according to 
the National Academies it “avoids a narrow focus on spe-
cific pathways and hypotheses and provides for a broad, 
holistic consideration of the mechanistic evidence”28. 
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Abstract | Endocrine- disrupting chemicals (EDCs) are exogenous chemicals that interfere with 
hormone action, thereby increasing the risk of adverse health outcomes, including cancer, 
reproductive impairment, cognitive deficits and obesity. A complex literature of mechanistic 
studies provides evidence on the hazards of EDC exposure, yet there is no widely accepted 
systematic method to integrate these data to help identify EDC hazards. Inspired by work to 
improve hazard identification of carcinogens using key characteristics (KCs), we have developed 
ten KCs of EDCs based on our knowledge of hormone actions and EDC effects. In this Expert 
Consensus Statement, we describe the logic by which these KCs are identified and the assays 
that could be used to assess several of these KCs. We reflect on how these ten KCs can be used  
to identify , organize and utilize mechanistic data when evaluating chemicals as EDCs, and we  
use diethylstilbestrol, bisphenol A and perchlorate as examples to illustrate this approach.
Risk
Probability that an agent will 
cause a disease or an adverse 
effect at a given level of 
exposure.
Differentiation
The process by which a multi- 
fate cell changes into a 
different more specialized cell.
Hazard
An agent that can cause 
disease or an adverse effect.
Carcinogens
Agents capable of causing 
cancer in living tissue.
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Indeed, the same National Academies report noted that 
KCs of other hazards, not just for carcinogens, should 
be developed28.
In this Expert Consensus Statement, we propose that 
chemicals that interfere with hormone action have iden-
tifiable KCs that relate to their ability to interact with 
key regulatory steps of hormone systems and that these 
KCs can be used to identify EDCs. Here, we identify 
the KCs that comprise the properties of all hormone 
systems. Ten KCs for EDCs are identified, representing 
the categories for the organization of the mechanistic 
evidence. Additionally, as with the KCs for carcinogens, 
the strength of the evidence is categorized for each KC 
during the hazard evaluation process28.
Methods
We assembled an international group of experts with 
knowledge of hormone systems, EDCs, hazard evalua-
tions and risk assessments, in vitro and in vivo screen-
ing tools, and carcinogenesis, with the goal of advancing 
the KC framework. A list of KCs for EDCs was devel-
oped by panel discussions to achieve consensus during 
a 2-day workshop and biweekly teleconferences. We 
next selected three chemicals to illustrate how these 
KCs can be used to identify the hazard of endocrine 
disruption: bisphenol A (BPA), diethylstilbestrol (DES) 
and perchlorate (Box 1). M.T.S., M.A.L.M. and R.T.Z. 
conceived the project and L.Z. facilitated the meeting 
funding. M.T.S. organized and chaired the workshop. 
M.A.L.M. developed the original set of KCs that were 
subsequently modified by the whole group. M.A.L.M. 
and R.T.Z. led the group discussions and subsequent 
biweekly teleconferences. All authors contributed 
ideas to these discussions and wrote specific sections 
of the manuscript.
Key characteristics of EDCs
The KCs of EDCs were developed by recognizing that 
there are common features of hormone regulation and 
action that are independent of the diversity of the effects 
of hormones during the life cycle. It follows that there 
are also features that characterize the actions of chemi-
cals that interfere with hormone regulation and action. 
Thus, the ten KCs identified (Fig. 1; TABle 1) are based 
on our evaluation of the scientific literature, both in 
the field of endocrinology and in endocrine disruptor 
research, including high- quality reports documenting 
the effects of chemical exposures on hormone systems 
(for example, see reFs29,30). Indeed, as no internationally 
harmonized ‘list’ of EDCs exists, we could not simply 
use the strategy of identifying ‘commonalities’ among 
EDCs in terms of their mechanisms. Moreover, such a 
list of commonalities among chemicals would be biased 
toward chemicals that are well studied, such as carcino-
gens and reproductive or thyroid toxicants, which repre-
sent the bulk of EDC research. Therefore, we capitalized 
on the extensive knowledge of hormone action to gen-
erate the ten KCs described in this Expert Consensus 
Statement. This list of KCs reflects current scientific 
knowledge and will probably evolve over time with new 
scientific discovery.
KC1: Interacts with or activates hormone receptors. 
All hormones act by binding to a specific receptor or 
receptors1. Inappropriate receptor activation can have 
profound negative effects on development and health, 
as illustrated by the formation of a scrotum and penis 
in genetic female humans exposed to androgens during 
gestation31. EDCs that inappropriately bind to and/or 
activate hormone receptors can produce adverse bio-
logical effects. There are numerous examples of chemi-
cals that cause adverse effects after binding to nuclear 
hormone receptors. For example, EDCs that inappro-
priately activate the oestrogen receptors (ERα and 
ERβ) during development increase the risk of infertil-
ity in both sexes as well as reproductive tract cancer 
in women and prostate cancer in men32, in addition to 
other reproductive effects. Another example of an EDC 
that activates hormone receptors is that of dichloro-
diphenyltrichloroethane (DDT; Box 1), which binds to 
ERα and ERβ33 and stimulates ER- dependent transcrip-
tional activation and proliferation34 in a variety of spe-
cies, including humans. Likewise, a specific hydroxylated 
congener of a polychlorinated biphenyl (PCB; Box 1) can 
activate human thyroid hormone receptor- β-mediated 
transcription1,35. EDCs can also activate cell mem-
brane receptors of peptide and steroid hormones. For 
instance, DDT binds to the transmembrane domain of 
the follicle- stimulating hormone receptor, a G protein- 
coupled receptor (GPCR), to allosterically enhance its 
stimulation of cAMP production36.
KC2: Antagonizes hormone receptors. EDCs can inhibit or 
block effects of endogenous hormones by acting as recep-
tor antagonists30. Although antagonism of membrane 
hormone receptors or intracellular hormone receptors 
can occur (as exemplified by drug discovery efforts37–39), 
most exogenous chemical research into antagonization 
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Box 1 | Sources of EDC exposures
Bisphenol A
Bisphenol a was considered for use as a pharmaceutical synthetic oestrogen in the 
1930s and is found today in a wide range of plastics, including medical and sports 
equipment, epoxy resins, the lining of food and beverage cans, dental sealants and 
other dental materials, paints, as a developer in thermal paper and in other papers, 
including food contact materials.
Diethylstilbestrol
Diethylstilbestrol was used to treat metastatic prostate cancer because of its 
oestrogenic effects in suppressing this hormone- responsive disease and was also 
prescribed to women during pregnancy to prevent miscarriage and premature labour, 
although it was ineffective for this purpose.
Dichlorodiphenyltrichloroethane
an organochlorine insecticide used to prevent diseases (such as malaria and typhus) 
carried by mosquito vectors that, as a result of widespread use, is a persistent organic 
pollutant found in many people worldwide.
Dichlorodiphenyldichloroethylene
a metabolite of dichlorodiphenyltrichloroethane that is also a persistent organic pollutant 
and common contaminant of the food supply, and is found in almost everyone worldwide.
Di(2-ethylhexyl) phthalate
a colourless and viscous plasticizer formerly used in the manufacture of polyvinyl 
chloride products, cosmetics, shower gels and shampoos.
Methoxyacetic acid
a metabolite of the solvent methoxyethanol that has been widely used in the 
semiconductor and painting industries.
Perchlorate
an inorganic ion that is widely manufactured for use in rocket propellant, matches, 
fireworks and other explosives, and is also a contaminant of hypochlorite bleach and 
drinking water supplies.
Polychlorinated biphenyls
a class of >200 chemicals formerly used in insulation and caulking that are persistent 
organic pollutants and common contaminants of the food supply.
eDC, endocrine-disupting chemical.
Epigenetic processes
Changes to DNA caused by 
actions, such as acetylation 
and methylation of DNA and 
histones and expression of 
non- coding rNAs, which 
change gene availability and 
expression but do not change 
DNA sequence.
of receptors has focused on antagonization of nuclear 
hormone receptors. Nuclear receptors that act as ligand- 
dependent transcription factors by mediating genomic 
regulatory responses can be antagonized by some EDCs. 
For example, dichlorodiphenyldichloroethylene, an 
organochlorine pesticide (Box 1), inhibits androgen bind-
ing to the androgen receptor (AR) and inhibits androgen- 
dependent transactivation of the AR in human40 and rat 
prostrate cells41. Other organochlorine pesticides (such as 
lindane and dieldrin, which is closely related to the organ-
ochlorine insecticide aldrin) also inhibit dihydrotestos-
terone binding to the AR. As androgens are key regulators 
of male sexual differentiation during fetal development, 
disruption of androgen action through AR antagonism in 
this period can permanently demasculinize male fetuses 
and lead to malformations of the genital tract42,43.
KC3: Alters hormone receptor expression. As hormone 
receptors mediate hormone actions1, their physio-
temporal pattern of expression dictates their response 
to hormone signals44,45. For example, receptor abundance 
can determine both the concentration of hormones that 
produces an effect as well as the magnitude of the effect 
itself in some situations46. EDCs can modulate hormone 
receptor expression, internalization and degradation. For 
example, di(2‐ethylhexyl) phthalate decreases the expres-
sion of the mineralocorticoid (aldosteron) receptor (MR) 
in the testis of adult mice47, where under normal condi-
tions, MR acts as a positive modulator of testosterone 
biosynthesis48. Further, BPA (Box 1) alters the expression 
of oestrogen, oxytocin and vasopressin receptors in brain 
nuclei49–53, and also reduces the proteasome- mediated 
degradation of ERβ54. The internalization of cell surface 
receptors is also disrupted by chemicals. For example, 
DDT prevents the internalization of the TSH receptor55.
KC4: Alters signal transduction in hormone- responsive 
cells. The binding of a hormone to a receptor triggers 
specific intracellular responses that are dependent on the 
receptor and tissue- specific properties of the target cell. 
Signal transduction mediated through both membrane 
and intracellular hormone receptors is altered by some 
EDCs. The signalling of two classes of receptors will be 
discussed here as they are the most extensively studied 
in the field of endocrinology and have EDC effects; these 
receptors are cell surface membrane receptors (such as 
GPCRs, receptor kinases, and kinase- linked and ionotropic 
receptors) and nuclear steroid hormone receptors.
Ionotropic receptor signalling can be perturbed by 
EDCs. For example, BPA blocks low glucose- induced 
calcium signalling in isolated pancreatic glucagon- 
secreting α- cells from adult male mice56. Furthermore, 
in 2018 it was shown that chemicals in ultraviolet filters 
disrupt calcium signalling in human sperm57,58.
Some membrane GPCRs bind steroids; among these, 
G protein- coupled oestrogen receptor (GPER; previ-
ously called GPR30) signalling is the best studied regard-
ing the EDC effects (for example, BPA59). Further, EDCs 
can attenuate or potentiate hormone action through sig-
nal transduction. For instance, in in vitro studies, the 
fungicide tolylfluanid impairs insulin action by reducing 
insulin receptor substrate 1 (reF.60), while methoxyacetic 
acid (Box 1) potentiates ligand- activated transcription 
and progesterone receptor- mediated transcription in a 
manner dependent on MEK1 and MEK2 activity61.
EDCs also affect signal transduction initiated by 
nuclear receptors. These effects include their interactions 
with coregulatory factors such as activators and repres-
sors, which are a key part of the molecular machinery 
determining the downstream response to nuclear hor-
mone receptor activation. The coregulatory factors 
for the steroid receptor coactivator (SRC) family are 
among the most studied in exogenous chemical research. 
For example, xenoestrogens (such as DES, PCBs, octyl-
phenol and BPA; Box 1) induce the recruitment of SRC1 
by ERα and ERβ in a dose- dependent manner62. BPA 
and its analogues also recruit SRC1 to thyroid hormone 
receptor- β63. Substantial evidence suggests that xeno-
estrogens, especially BPA, increase SRC1 expression, as 
shown in the rat hypothalamus64,65 and in human breast 
cancer cell lines66. Another EDC, 4-methylbenzylidene 
camphor (which is used in ultraviolet filters), also 
increases SRC1 expression in female rat hypothalamus67.
KC5: Induces epigenetic modifications in hormone- 
producing or hormone- responsive cells. Hormones can 
exert permanent effects — especially during development 
and differentiation — by modifying epigenetic processes, 
including DNA and histone modifications and non- coding 
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RNA expression. An EDC that interferes with hormone 
action can do so by interfering with the ability of a hor-
mone to induce these epigenetic changes or by inducing 
these epigenetic changes to interfere with hormone action 
(such as by altering the expression or action of a hormone 
receptor or the transcription of hormone- responsive 
genes68,69). For example, the pesticide methoxychlor 
increases the expression of the DNA methyltransferase 
DNMT3B to hypermethylate DNA, including ESR2 
(which encodes ERβ) in the ovary of developmentally 
exposed rats70. In addition, di(2-ethylhexyl) phthalate 
inappropriately demethylates MR DNA in the testis of 
male mice47. EDCs can also change the expression of non- 
coding RNAs, as is seen with PCBs altering the develop-
mental trajectories of hypothalamic microRNA expression 
in a sexually dimorphic manner71 as well as BPA and 
phthalates affecting microRNA expression in placental, 
Sertoli and breast cancer cell lines72.
Signal transduction
Epigenetic alterations
Hormone synthesis
Hormone transport
Hormone distribution or 
circulating hormone levels
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endocrine-disrupting chemicals
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Fig. 1 | The key characteristics of endocrine- disrupting chemicals. Arrows identify the ten specific key characteristics 
(KCs) of endocrine- disrupting chemicals (EDCs). The ± symbol indicates that an EDC can increase or decrease processes 
and effects. KC1 states that an EDC can interact with or activate hormone receptors. KC2 states that an EDC can 
antagonize hormone receptors. KC3 states that an EDC can alter hormone receptor expression. KC4 states that an EDC 
can alter signal transduction (including changes in protein or RNA expression, post- translational modifications and/or  
ion flux) in hormone- responsive cells. KC5 states that an EDC can induce epigenetic modifications in hormone- producing 
or hormone- responsive cells. KC6 states that an EDC can alter hormone synthesis. KC7 states that an EDC can alter 
hormone transport across cell membranes. KC8 states that an EDC can alter hormone distribution or circulating hormone 
levels. KC9 states that an EDC can alter hormone metabolism or clearance. KC10 states that an EDC can alter the fate  
of hormone- producing or hormone- responsive cells. Depicted EDC actions include amplification and attenuation of 
effects. Ac, acetyl group; Me, methyl group.
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Further to these data, a study on long non- coding 
RNAs found that oestradiol, BPA and DES induced 
HOX antisense intergenic RNA (termed HOTAIR) in 
human breast cancer cells73. In the presence of BPA and 
DES, the ER- binding region of the HOTAIR promoter 
was enriched by trimethylation on lysine 4 of histone 3 
(H3K4) and by H3K4-specific methyltransferases, which 
are known to activate transcription73 (TABle 2). Moreover, 
developmental BPA exposure enhances H3K4 trimethyl-
ation on genes, which are subsequently more sensitive 
to regulation by testosterone68. Oestradiol and DES also 
reduce trimethylation of lysine 27 on histone H3 in the 
developing uterus of rats74.
KC6: Alters hormone synthesis. Hormone synthesis is 
regulated by both intracellular and distant endocrine 
feedback mechanisms. For example, thyroid hormone 
synthesis is controlled by a combination of TSH activa-
tion of their receptors on thyrotrophs as well as intracel-
lular cAMP, iodine uptake and the activation of various 
enzymes16. After transcription and translation, proteins 
and peptide hormones are packaged into secretory 
vesicles where they can be stored75. By contrast, ster-
oid hormone synthesis, including the transformation 
of a pro- hormone to a hormone, occurs more or less 
simultaneously with hormone activity1. Some EDCs 
are known to interfere with hormone synthesis. For 
example, perchlorate can block the uptake of iodine 
into thyroid cells, thereby inhibiting thyroid hormone 
synthesis76 (Box 1; TABle 2) and phthalates can reduce 
testosterone synthesis in the fetal rat testis, resulting in 
testosterone insufficiency77,78.
By contrast, the herbicide atrazine apparently 
increases oestrogen synthesis in peripubertal male 
mice, as evidenced by a decrease in serum levels of tes-
tosterone coupled to an increase in circulating levels 
of oestrogen and in the activity of the aromatase that 
synthesizes oestrogen from testosterone79. Additionally, 
several neonicotinoid pesticides block the JAK–STAT3 
pathway to enhance the promoter usage and expression 
of CYP19 (aromatase), the gene that encodes the enzyme 
that converts testosterone to oestrogen80.
KC7: Alters hormone transport across cell mem-
branes. Due to their lipophilicity, steroid hormones 
(including oestrogens, androgens, progestins and adre-
nal steroids) can move through membranes passively. 
Other hormones (such as amine, peptide, protein and 
Table 1 | Key characteristics of EDCs and representative standardized tests that address them
Key characteristics Examples of relevant streams 
of mechanistic evidence
Guideline description (species) [agency and guideline 
number]a
KC1. Interacts with or activates 
hormone receptors
Binding or agonism of hormone 
receptors
Androgen Receptor Binding (rat) [US EPA 890.1150]; Estrogen 
Receptor Binding (rat) [US EPA 890.1250, OECD TG 493]; 
Estrogen Receptor Transcriptional Activation (human stable 
transfection) [US EPA 890.1300, OECD TG 455]; Androgen 
Receptor Binding (rat) [US EPA 890.1150]; Androgen Receptor 
Transcriptional Activation (human stable transfection) [OECD 
TG 458]; Uterotrophic (rat) [US EPA 890.1600, OECD TG 440]; 
Hershberger [US EPA 890.1400, OECD TG 441]
KC2. Antagonizes hormone receptors Antagonism of nuclear or cell surface 
hormone receptors
Estrogen Receptor Transcriptional Activation (human) [OECD 
TG 455]; Androgen Receptor Transcriptional Activation (human) 
[OECD TG 458]; Hershberger [US EPA 890.1400, OECD TG 441]
KC3. Alters hormone receptor 
expression
Abundance, distribution and 
degradation of hormone receptors
None
KC4. Alters signal transduction in 
hormone- responsive cells
Abundance of post- translational 
modifications, cofactors, transcription 
factors and transcripts, and activity 
of associated enzymes
None
KC5. Induces epigenetic modifications 
in hormone- producing or hormone- 
responsive cells
Chromatin modifications, DNA 
methylation and non- coding RNA 
expression
None
KC6. Alters hormone synthesis Expression or activity of enzymes or 
substrates in hormone synthesis
Aromatase (human) [US EPA 890.1200]; Steroidogenesis 
(human) [US EPA 890.1550, OECD TG 456]
KC7. Alters hormone transport across 
cell membranes
Intracellular transport, vesicle dynamics 
or cellular secretion
None
KC8. Alters hormone distribution 
or circulating hormone levels
Blood protein expression and binding 
capacity , blood levels of pro- hormones 
and hormones
None
KC9. Alters hormone metabolism 
or clearance
Inactivation, breakdown, recycling, 
clearance, excretion or elimination  
of hormones
None
KC10. Alters fate of hormone- producing 
or hormone-responsive cells
Atrophy , hyperplasia, hypertrophy , 
differentiation, migration, proliferation 
or apoptosis
None
EDC, endocrine- disrupting chemical; OECD, Organisation for Economic Co- operation and Development; TG, test guideline; US EPA , US Environmental Protection 
Agency. aOnly assays that serve as the basis of regulatory decisions of the OECD and US EPA are provided.
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thyroid hormones) must be selectively transported 
across membranes either to gain entrance to and/or to 
exit the cell81. These selective and passive transport pro-
cesses can be disrupted by EDCs. One well- delineated 
example of impaired selective transport by an exogenous 
chemical is low dose BPA, which reduces calcium entry 
into mouse pancreatic β- cells to reduce insulin secretion 
from vesicles82 (TABle 2). Additionally, the anti- corrosive 
and fungicidal chemical imidazoline modulates ions to 
enhance insulin secretion83, and the passive secretion of 
Table 2 | Key characteristics of EDCs applied to three EDCs
Key characteristic Mechanistic evidence for DES Mechanistic evidence for BPA Mechanistic evidence for 
perchlorate
KC1. Interacts with 
or activates hormone 
receptors
DES activates nuclear and membrane 
ER in mammals, including humans56,109
BPA activates nuclear ERs140,141, membrane 
ER142 and GPER143 in a variety of species
No evidence
KC2. Antagonizes 
hormone receptors
DES antagonizes oestrogen- related 
receptor- γ109
BPA antagonizes androgen receptor144 No evidence
KC3. Alters hormone 
receptor expression
Developmental DES exposure 
decreases ERβ expression in the 
developing female rat reproductive 
track102
BPA increases the expression of ER mRNA , 
and its location, in specific regions of the 
brain in mice exposed during gestation145
No evidence
KC4. Alters signal 
transduction in hormone- 
responsive cells
DES increases ERα- dependent 
transcriptional activity of enhancers 
proximal to a high density of ERα 
binding sites in the uteri of mice7; 
DES induces recruitment of SRC1 by 
ERα and ERβ in a dose- dependent 
manner62
BPA- induced proliferation of Sertoli TM4 
cells is mediated by the induction of ERK 
phosphorylation; in a human testicular 
seminoma cell line (JKT-1), BPA activates 
cAMP- dependent and cGMP- dependent 
protein kinase pathways to phosphorylate 
CREB59
No evidence
KC5. Induces epigenetic 
modifications in 
hormone- producing or 
hormone- responsive cells
DES reduces trimethylation of H3K27 
in the developing uteri of rats74; 
the ER- binding region of the long 
non- coding RNA HOTAIR promoter 
is enriched by trimethylation 
on H3K4 and by H3K4-specific 
methyltransferases in human breast 
cancer cells exposed to DES73
BPA affects promoter- specific methylation 
in brain, prostate and human breast cancer 
cells73,146,147; the ER- binding region of the 
long non- coding RNA HOTAIR promoter 
is enriched by trimethylation on H3K4 
and by H3K4-specific methyltransferases 
in human breast cancer cells73; in mouse 
prostate, neonatal exposure to BPA activates 
the histone methyltransferase MLL1 to 
persistently increase H3K4 trimethylation at 
genes associated with prostate cancer147
No evidence
KC6. Alters hormone 
synthesis
DES decreases levels of the sex 
hormone precursor DHEA as well 
as downstream sex hormones, e.g. 
testosterone and oestrone in men148 
and oestradiol in women149
BPA inhibits steroidogenesis in the rat 
testis150; BPA reduces cytochrome p450 
aromatase levels and the expression of other 
steroidogenic regulatory proteins151
Perchlorate directly interferes 
with thyroid hormone 
synthesis by inhibiting iodide 
uptake through the human 
sodium–iodide symporter on 
thyrocytes, thereby reducing 
free intracellular iodine for the 
synthesis of thyroid hormone152
KC7. Alters hormone 
transport across cell 
membranes
No evidence Low BPA doses reduce insulin secretion from 
vesicles of pancreatic islet β- cells56
No evidence
KC8. Alters hormone 
distribution or circulating 
levels of hormones
DES increases circulating levels of 
SHBG while decreasing circulating 
levels of LH, TSH, FSH, DHEA , 
testosterone and oestrone in 
humans88,148,149,153
In men, BPA exposure is associated 
with increased levels of SHBG87,154 as 
well as decreased circulating levels of 
androstenedione and free testosterone87
No evidence
KC9. Alters hormone 
metabolism or clearance
In utero exposure to DES correlates 
with a shift in women’s oestrogen 
metabolism with a relative decrease 
in 2-hydroxylation155
No evidence No evidence
KC10. Alters fate of 
hormone- producing or 
hormone- responsive cells
Developmental exposure to DES 
increases proliferation in the 
developing female rat reproductive 
tract and abnormal mammary gland 
morphology102,106; DES induces 
keratinization of the vaginal 
epithelium of mice104,105
Developmental exposures to BPA alter the 
differentiation of mammary epithelial cells 
and increase the number of alveolar buds 
(structures that eventually produce milk in 
lactating females) in the mammary gland156,157; 
BPA also increases the proliferation index in 
the mammary gland158, pancreas8 and uterine 
endothelial cells159, among others
No evidence
BPA , bisphenol A ; CREB, cAMP- response-element binding protein; DES, diethylstilbestrol; DHEA , dehydroepiandrosterone; EDC, endocrine- disrupting chemical; 
ER , oestrogen receptor ; ERK , extracellular signal- regulated kinase; FSH, follicle- stimulating hormone; GPER , G protein- coupled oestrogen receptor ; LH, luteinizing 
hormone; SHBG, sex hormone- binding globulin; SRC1, steroid receptor coactivator 1.
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corticosterone from rodent adrenal glands is reduced by 
low- dose dichlorodiphenyldichloroethylene84.
KC8: Alters hormone distribution or circulating levels 
of hormones. Hormones typically circulate throughout 
the body in the blood at low concentrations, often in the 
parts per billion and trillion range85. Depending on its 
chemistry, a circulating hormone is either transported 
‘free’ (not bound to serum protein) with or without 
conjugation (such as glucuronidation or sulfation) 
or is circulated bound to various proteins. EDCs can 
alter hormone bioavailability by interfering with the 
distribution of hormones in hormone- responsive tissues 
or with the circulation of hormones, including by dis-
placing hormones from their serum binding proteins, 
which can lead to impaired active hormone delivery to 
target tissues. For example, BPA causes a concentration- 
dependent decrease in circulating levels of testosterone 
in male rats and men, and the pesticide malathion 
reduces testosterone levels in serum, testis and ovaries 
in several animals experimentally30,86,87. When DES is 
administered to men intravenously, reductions in total 
(a sixfold reduction) and free (a 20% reduction) testos-
terone and oestrogen (a fivefold reduction) are concurrent 
with an over sevenfold increase in serum concentration 
of sex hormone- binding globulin (SHBG)88 (TABle 2).
KC9: Alters hormone metabolism or clearance. The var-
ious hormone types (such as protein, peptide, steroid or 
thyroid) are inactivated differently. For example, after 
secretion, protein hormones (for example, gonado-
tropins) are inactivated when they are broken down by 
proteases in the blood. By contrast, steroid and thyroid 
hormones are metabolized by enzymes that render them 
hormonally inactive and increase their water solubil-
ity so that they can be removed from the bloodstream 
and excreted1.
EDCs can alter the rates of inactivation, including the 
metabolic degradation or clearance, of hormones, which 
could alter hormone concentrations and ultimately their 
activity. For example, a large number of chemicals acti-
vate glucuronidases, which increase thyroid hormone 
clearance from the blood89. Furthermore, sulfation 
by oestrogen sulfotransferase, which reduces the rate 
of oestrogen clearance from the blood, is inhibited by 
several coplanar hydroxylated PCB metabolites, a major 
meta bolite of the fungicide hexachlorobenzene and 
several chlorophenolic wood preservatives90.
KC10: Alters the fate of hormone- producing or hormone- 
responsive cells. Hormones affect tissue structure and 
organization by affecting cell fate (for example, cellular 
proliferation, migration or differentiation) and/or death 
(that is, apoptosis or necrosis) during development and 
adulthood91–93. In adulthood, many healthy endocrine 
organs have a fairly stable number of cells (including 
adrenals and pancreas), whereas other endocrine organs 
or hormone- responsive tissues depend on cell growth 
for normal function (such as the testicles to form sperm, 
the uterine endometrium and vaginal lining). EDCs 
can alter the total number or positioning of cells in 
hormone- producing or hormone- responsive tissues by 
disrupting or promoting differentiation, proliferation, 
migration or cell death. For example, thyroid hormone 
controls cell proliferation and apoptosis in the devel-
oping cerebellum and PCBs can interfere with thyroid 
hormone signalling to cause abnormal morphology later 
in life94. Female mice exposed to oxybenzone, a chemical 
ultraviolet filter found in personal care products, during 
pregnancy and lactation have increased mammary epi-
thelial cell proliferation, which is observed even weeks 
after exposures cease95. In cultured human endometrial 
stromal cells, treatment with the antibacterial agent tri-
closan increases decidualization96. In the brain (antero-
ventral periventricular nucleus of the hypothalamus), 
developmental exposure to a PCB mixture substan-
tially decreases the numbers of cells expressing ERα in 
adult female but not male rats97. Further, tebuconazole, 
a common fungicide, impairs placental migration, a 
process essential to placentation98.
Application of the ten KCs
In the following sections we illustrate how the KCs can 
be used to organize and integrate mechanistic data with 
data on adverse endocrine effects in humans and in 
experimental models in an analysis designed to identify 
an EDC hazard. Sources of exposure, which could be 
considered to identify risk, are found in Box 1. Note that, 
for two of these examples, DES and BPA, substantial evi-
dence exists for almost all the KCs yet for perchlorate 
strong evidence is available for only one KC (TABle 2). 
Thus, the number of KCs associated with a specific 
exposure is not predictive of the EDC hazard as much 
as the relationship of the KC to hormone action.
Example EDC: DES. In the human phenotype (of note, 
‘human phenotype’ describes the clinical outcomes and 
epidemiology that characterize the adverse endocrine 
effects), women who were exposed in utero exhibit a 
higher incidence of breast cancer and clear cell carci-
noma of the vagina99, in parallel to studies in mice (see 
below). Prenatal exposure to DES also is associated 
with disruption of the growth of hormone- sensitive 
structures in these daughters, with changes such as 
cellular abnormalities of the vaginal lining, increased 
breast size and abnormally shaped uteri in adolescents 
and young women100,101. Boys who were exposed to DES 
in utero are also prone to genital birth defects such as 
hypo spadias and cryptorchidism102. Emerging evidence 
suggests that the effects of DES persist into the next 
(F2) generation; for example, the grandsons of women 
who took DES during pregnancy are at increased risk of 
genital defects103.
In the animal phenotype (of note, ‘animal phenotype’ 
describes the pathology and physiology observed in 
experimental animal models), DES was first identified 
as an oestrogen following the discovery that it induces 
keratinization of the vaginal epithelium — an oestro-
genic effect — in mice104,105. In utero exposure to DES 
induces uterine deformities, reproductive tract can-
cer and abnormal mammary gland morphology in 
female rodents, while neonatal exposure leads to penile 
deformity and low sperm counts in male rodents106. DES 
increases body weight in livestock and subclinical doses 
Distribution
The transfer of a substance 
from one location to another 
within the body following its 
absorption.
Clearance
The elimination and removal of 
a substance from a tissue or 
the organism as a whole.
Decidualization
A differentiation process that 
occurs in the uterus to promote 
placental formation.
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induce obesity in rodents107. Multigenerational effects 
of DES have been documented in experimental animal 
studies, including vaginal adenocarcinomas observed 
in the granddaughters of mice that were exposed in 
adulthood108.
Mechanistic data (of note, the KCs are revealed in 
‘mechanistic data’ from human and model cells, model 
organisms and through the use of biomarkers) show 
that DES exhibits nine of the ten KCs of an EDC and 
is noteworthy for the abundance of mechanistic data 
in humans (TABle 2). DES is an agonist of nuclear and 
membrane ER56,109, including to SRC1 (reF.62) recruit-
ment and epigenetic modifications73,74 that activate 
ER- responsive transcription. For example, DES induces 
gene expression of several oestrogen- responsive HOXA 
genes necessary for differentiation of human female 
reproductive tract cells, which is probably responsible for 
the metaplastic effects of DES110,111. Further, DES expo-
sure alters circulating concentrations of hormone and 
SHBG in humans. When DES is administered to men 
intravenously, total and free levels of testosterone and oes-
trogen are reduced (a sixfold reduction, 20% reduction 
and fivefold reduction, respectively) concurrently with 
an over sevenfold increase in levels of SHBG88,108,112. The 
KCs of DES identified among mechanistic studies, along 
with the evidence from human and other animal studies, 
indicate that effects of DES on the reproductive axes of 
female and male humans and rodents are mediated by 
numerous DES KCs that perturb oestrogen action.
Example EDC: BPA. In the human phenotype, there are 
now >100 epidemiology studies that show associations 
between BPA and adverse outcomes such as obesity, 
diabetes mellitus, female infertility, male sexual dysfunc-
tion, reduced birth weight and atypical neurobehaviours 
in children, among others113. Although many of these 
studies are cross- sectional, others are longitudinal, 
providing stronger evidence for causal relationships 
between exposures and effects.
In the animal phenotype, hundreds of studies demon-
strate that, in rodents, even low doses of BPA can disrupt 
development of the brain, male and female reproductive 
tracts, and mammary gland and metabolic tissues under 
endocrine control, among others114. BPA can also induce 
precancerous and cancerous lesions of the mammary 
gland and prostate115.
Mechanistic data show that thousands of mechanis-
tic scientific papers on BPA have been published that 
provide substantial evidence for nine of the ten KCs 
described above (TABle 2). Experimental studies have 
shed light on the molecular mechanisms that explain the 
actions of BPA on human and animal phenotypes. These 
studies have revealed that BPA binds to ERα and ERβ, as 
well as GPER, membrane ER, thyroid hormone receptor 
and AR116. BPA then causes the enrichment of H3K4 
trimethylation and H3K4-specific methyltransferases 
at the ER- binding region of the HOTAIR promoter, and 
these enrichments are known to activate transcription 
in oestrogen- responsive cells73. The activation of ER 
by BPA has multiple effects on organs in various spe-
cies, for example, BPA activates ERβ- mediated ion flux, 
which underlies the reduction in insulin secretion from 
pancreatic β- cells in response to BPA treatment82. The 
aforementioned KCs of BPA are consistent with the 
known mechanisms that underlie the diverse adverse 
effects that have been associated with BPA exposure in 
humans and other animals.
Example EDC: perchlorate. In the human phenotype, 
measures of urinary perchlorate — a biomarker of per-
chlorate exposure — in pregnant women are linked to 
reduced maternal levels of thyroid hormone in several, 
but not all, studies117–120. However, because newborn 
babies are uniquely sensitive to suppression of thyroid 
hormone synthesis121, the relationship between perchlo-
rate exposure and circulating levels of thyroid hormones 
should be evaluated in this population. Among the five 
studies in which thyroid hormone levels were meas-
ured within a day of birth, there is consistent evidence 
that newborn babies from communities that have been 
exposed to perchlorate have lower T4 levels and higher 
TSH levels and thyroid disease than those from unex-
posed communities122. The sufficiency of dietary iodine 
intake in a population is also likely to be a contribut-
ing factor to the variability in epidemiological associa-
tions between circulating perchlorate levels and thyroid 
hormone levels.
In the animal phenotype, low doses of perchlorate 
reduces serum levels of T4 in pregnant rats and their 
pups123 and impairs synaptic function in the adult hippo-
campus124. This finding supports the negative associa-
tion between perchlorate and levels of T4 in the human 
epidemiological studies described in the previous 
section.
Mechanistic data show that perchlorate has strong 
evidence for only one KC; yet, it is a critical KC as it 
provides biological plausibility to the human and animal 
findings. Perchlorate inhibits thyroid hormone synthesis 
(KC6; TABle 2) by acting as a potent competitive inhib-
itor of iodide uptake through the sodium–iodide sym-
porter from humans, rodents and other vertebrates76,125. 
This symporter protein normally transports iodide 
across cell membranes in the thyroid gland, gut lining, 
placenta, the lactating breast and the choroid plexus126. 
Collectively, the aforementioned research on perchlorate 
suggests that perchlorate reduces thyroid hormone levels 
in humans and other animals by limiting the amount 
of iodide available for the synthesis of these hormones.
Application of the ten KCs to identify EDCs
The KCs of carcinogens have been successfully applied 
by the IARC Monographs Programme to evaluate the 
mechanistic data for >30 suspected carcinogens127. 
Within the context of IARC, carcinogens are identi-
fied by four separate data streams: human exposure, 
tumours in humans, tumours in animals and mecha-
nistic. The mechanistic data identified through the KCs 
of carcinogens support the interpretation of these other 
data streams by freeing the reviewers from linking spe-
cific mechanisms to specific tumours, which is a nearly 
impossible task. Similarly, we envision that the KCs of 
EDCs will provide a structure for searching and organ-
izing the relevant literature on mechanistic information 
in support of an evaluation of a chemical for endocrine 
Biomarkers
Measurable substances in an 
organism whose presence is 
indicative of some phenomenon 
such as disease, infection or 
environmental exposure.
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disruption (Box 2). These KCs are not a checklist; any 
specific application of the KC approach to identifying 
EDCs will depend on the extent of evidence on the 
chemical as well as on the goals of the end- user (Box 3).
Depending on the end- users’ chosen parameters, such 
as the definition of the EDC used, the types and availabil-
ity of data that can inform the evidence stream, and/or 
budget, end- users might wish to compress several KCs 
into a larger category or omit certain KCs in their EDC 
definition. It is critical in all circumstances to recognize 
that identifying an EDC is not merely counting the sum 
of KCs with supporting evidence. Hormones generally 
act through entire systems, and one KC might be suffi-
cient to disrupt an entire system. Strong evidence for one 
KC could be enough to support identification of an EDC, 
as is illustrated by perchlorate, which only has one KC yet 
its endocrine- disrupting activity is strongly supported by 
human and experimental evidence. Hence, incorpora-
tion of mechanistic data into EDC hazard identification 
should not be thought of in terms of a minimum number 
of KC ‘hits’, but rather in terms of whether the chemical 
interferes with a key event in hormone action consistent 
with causing an adverse effect.
Assays to evaluate KCs
Some mechanistic assays have been developed to screen 
potential EDCs in a regulatory context, though these 
are limited to measuring chemicals that interact with 
sex steroid nuclear receptors or alter the synthesis of sex 
steroids (such as KCs 1, 2 and 6; TABle 1). High- throughput 
mechanistic assays, on the other hand, are abundantly 
available in the suite of ToxCast128 and Tox21 (reF.129) 
assays, which screen thousands of chemicals for a vari-
ety of toxicity pathways, including endocrine disruption. 
These high- throughput assays have not undergone inter-
national validation, and therefore regulatory authori-
ties use the resulting data only in certain contexts. For 
example, results of a ToxCast ER model that integrates 
data from 18 in vitro assays130,131 are accepted by the US 
Environmental Protection Agency in lieu of the rodent 
in vivo uterotrophic assays to screen for the oestrogenic 
effect of chemicals. In addition, high- throughput mecha-
nistic data can be part of the data used to satisfy the 
European regulatory criteria of an endocrine disruptor19.
Despite the hundreds of toxicity end points in these 
high- throughput platforms, assays that assess several 
KCs of EDCs are not well represented or are absent. 
This absence of data presents an opportunity to use the 
KCs of EDCs to identify assay development needs. In 
addition to the high- throughput platforms used by fed-
eral agencies to screen for activity, the published in vitro, 
in vivo and chemoinformatics literature can inform the 
evaluation of EDC properties. Indeed, the KCs of EDCs 
can be used to identify search terms for the transparent 
acquisition of the extensive research emanating from 
academic and government research laboratories to 
contribute to the identification of EDCs (Box 2).
Effect on risk assessment
Over the past several decades, innovative methods for 
identifying chemical interactions with a molecular tar-
get, such as a hormone receptor or enzyme, have become 
increasingly available. These interactions might initiate 
a sequence of downstream biological effects that lead 
to adverse outcomes, yet molecular effects and adverse 
responses are not usually evaluated in the same test. 
Establishing causal linkages between these molecu-
lar events and adverse outcomes therefore requires an 
organizational framework to evaluate biologically plau-
sible connections between responses at different levels 
and from different methods. Mode of action analyses 
were developed in an attempt to link key events in a 
theoretical biological sequence (such as carcinogenicity 
and endocrine effects)132,133. Adverse outcome pathways are 
an expansion of mode of action concepts that include a 
molecular initiating event and an adverse outcome in an 
organism, which are linked by all key events measured 
at various levels of organization134. Both mode of action 
and adverse outcome pathways are linear, reductive 
models of complex physiology but might nonetheless 
be helpful for understanding how chemicals exert their 
toxic effects135.
A challenge to the practical application of mode of 
action and adverse outcome pathway approaches for 
chemical safety decision- making is the limitation in 
the current understanding of disease processes, which 
could be shown to be incorrect or incomplete136. This 
limitation was recognized by Sir Bradford Hill, who for-
malized the research of causality in humans while not-
ing that “what is biologically plausible depends upon the 
biological knowledge of the day”137.
The KCs approach we describe herein can be viewed 
as identifying molecular initiating events or early key 
events in both mode of action and adverse outcome 
pathway frameworks based on our current knowledge 
of the molecular mechanisms of hormone action as well 
as the role of hormones in development, health and 
disease. Using KCs to assemble mechanistic data about 
a putative EDC does not require an exhaustive under-
standing of how the characteristics are causally linked 
Box 2 | Recommended uses of the key characteristics of EDCs
•	Systematically search the scientific literature for mechanistic data by using 
appropriate combinations of keyword terms (such as controlled ontologies) to 
reproducibly identify end points relevant to the key characteristics (KCs).
•	Screen the literature based on inclusion and exclusion criteria consistent with the  
KC definitions. The resulting included papers can then be further evaluated in more 
detail based on design and reporting features as defined by the end- user.
•	organize and integrate the gathered evidence on endocrine disruption across data 
streams.	Such	data	might	arise	from	molecular	epidemiology	studies,	in vivo	and	
in vitro	tests	in	experimental	models,	high-	throughput	tests	and	in	silico	modelling.	
The latter data sources might be germane when the former mechanistic data sources 
are sparse.
•	Characterize the mechanistic evidence for an endocrine- disrupting chemical (eDC) 
as ‘strong’, ‘limited’ or ‘inadequate’ to reflect the wide variance in the extent and 
quality of evidence for any given KC, and following the approach of the International 
agency for research on Cancer139.
•	Free the investigator from ‘connecting the dots’ between the so- called ‘molecular 
initiating event’ and a specific mode of action or adverse outcome pathway.  
In combination with phenotypic data from epidemiological and animal studies,  
this strategy represents an important and practical addition to hazard identification.
•	evaluate the relevant literature for similar effects of disparate chemicals, enabling 
them to be grouped for possible classification as eDCs.
ToxCast
A multi- year effort based at the 
Us environmental Protection 
Agency and launched in 2007 
that uses automated chemical 
screening technologies, called 
high- throughput screening 
assays, to expose living cells, 
isolated proteins or other 
biological molecules to 
chemicals.
Tox21
A federal collaboration among 
the Us environmental 
Protection Agency, NiH 
(including National Center for 
Advancing Translational 
sciences and the National 
Toxicology Program at the 
National institute of 
environmental Health 
sciences) and the Us Food and 
Drug Administration.
Mode of action
A functional or anatomical 
change, at the cellular level, 
resulting from the exposure of 
a living organism to a 
substance.
Adverse outcome pathways
The structured representation 
of biological events leading in a 
linear way to an adverse effect, 
beginning with a molecular 
initiating event and ending in 
an adverse outcome.
Molecular initiating event
The point at which a chemical 
first effects a biological target.
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to the endocrine response or an a priori hypothesis 
about the mode of action or adverse outcome pathways. 
Instead, the KCs are based on the common properties of 
hormone systems during vertebrate developmental and 
adult life stages. In this manner, the KC approach avoids 
“a narrow focus on specific pathways and hypotheses” 
and instead “provides for a broad, holistic consideration 
of the mechanistic evidence”28.
Conclusions
The KCs of EDCs are the functional properties of agents 
that alter hormone action. This emphasis is both unique 
and powerful in that these KCs comprise the major 
mechanisms by which hormone systems can be dis-
rupted, including by interfering with what they do, how 
they do it and how they are controlled. The literature 
on the fundamental and clinical actions of hormones is 
extremely large and the KCs, as we have proposed them, 
open the process of EDC hazard identification to this lit-
erature. An essential element of the KC approach is that 
it superimposes on the fundamental endocrine frame-
work the mechanisms by which chemicals can interfere 
with these systems. The KC approach is also adaptable 
in that users can collapse KCs (such as combine KC1 and 
KC2) if their given situation is advanced by this. The ten 
KCs described herein can also be mapped to current and 
future assays used to identify EDCs.
The KCs are agnostic with respect to current or future 
knowledge of downstream health hazards and mechanis-
tic pathways. As we learn more about chemical actions 
on endocrine systems, the KCs should be updated to 
reflect this new information. The value of this approach 
for EDCs, as for carcinogens, is that the inevitable mech-
anistic gaps in the delineation of the complete pathway 
from exposure to downstream health hazards need 
not hamper the identification of key chemical charac-
teristics that lead to phenotypic end points. Even for 
the case of BPA, which has been more intensely studied 
than perhaps any other EDC138, there are gaps in our 
understanding of the complete molecular pathways by 
which BPA produces observed health effects. Indeed, the 
same can be said for well- known exposure–disease rela-
tionships such as cancers induced by tobacco smoking 
and developmental neurotoxicity from lead exposure. In 
the absence of ‘complete’ knowledge, the recommended 
KCs of EDCs approach can systematically identify gaps 
in data and therefore set research priorities through 
the process of hazard identification. The utility of this 
approach is evidenced by the 2018 paper demonstrating 
the effect of KCs in carcinogen hazard identification127.
We recommend that efforts to identify and classify a 
chemical as an EDC utilize our KCs of EDCs approach 
in conjunction with other data (including epidemiolog-
ical and experimental animal data) as we exemplified in 
the section ‘Application of the ten KCs’. Similar to the 
KCs of carcinogens, the KCs of EDCs can distil com-
plex EDC mechanistic research from human and animal 
studies into a transparent approach.
As highlighted by the demonstration that three dif-
ferent well- known EDCs exhibit different characteris-
tics of interference with endocrine systems supporting 
1–9 KCs, we emphasize that the KCs should not be used 
as a checklist. We identify applications for the KCs, 
including their use by agencies that have been charged 
with risk evaluation and EDC classification (Box 3). 
Future directions for the KCs of EDCs should include 
the development of a controlled ontology of search terms 
to facilitate their widespread application.
In conclusion, the KCs of EDCs approach provides 
a universal framework for organizing mechanistic evi-
dence for hazard identification that can be the founda-
tion for the implementation of EDC risk assessments 
worldwide. This approach is a highly novel advancement 
in the EDC field.
Published online 12 November 2019
Box 3 | Applications for key characteristics of EDCs
Identifying the hazards of a chemical as an endocrine- disrupting chemical (EDC)
We recommend that the key characteristics (KCs) be used to support hazard identification, integrated with human 
epidemiological, clinical and animal data streams when available, for endocrine disruption.
Grouping chemicals due to common hazard characteristics
Identifying common distributions of KCs among chemicals might prove useful for integrating chemicals in cumulative 
hazard assessment, as is exemplified by the receptor activity- based toxic equivalency evaluation of a large class of 
structurally similar industrial chemicals known as dioxin- like chemicals. Toxic equivalency is a weighted system used by 
regulatory agencies to evaluate the hazard of mixtures of dioxin- like halogenated aromatic hydrocarbons, which bind the 
aryl hydrocarbon receptor with varying affinities and/or activities, where the most potent chemical, tetrachlorodibenzo- 
p-dioxin, is ranked 1. Historically, chemicals of concern have often been replaced by chemicals that are structurally 
similar and later found to pose similar risks. The KCs approach might help avoid a regrettable substitution by revealing 
undesirable mechanistic characteristics of potential replacement chemicals early in the product development phase.
Providing a foundation for risk assessments
The KCs enable objective consideration of the intrinsic hazard of eDCs, knowledge that can then be applied by individual 
geopolitical jurisdictions in the context of eDC exposure levels in their populations. Data mapped to a specific KC might 
support dose–response inferences for both data rich and data poor chemicals.
Prioritizing data and testing protocol gaps
organizing mechanistic data into KCs will help elucidate those KCs where data are lacking. This will in turn help prioritize 
further studies of the chemical or chemicals of interest and the development of new testing protocols through expert- 
guided mapping of assays to KCs. as more and better assays are developed and validated, we envision the KCs being 
systematically evaluated through a series of specific tests.
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